Awaiting price reaction for this filing.
Marksans Pharma reported record-high annual revenue and profits for FY25, with operating revenue rising 20.5% YoY to Rs. 2,622.8 cr and PAT growing 21.5% to Rs. 382.6 cr. EPS for the year stood at Rs. 8.4, up 21.3% YoY. The US market was the key growth driver, expanding 34.7% YoY to Rs. 1,236.6 cr, while UK & Europe grew 9.2% and Australia & NZ grew 15.5%. Q4FY25 was strong with revenue up 26.5% YoY to Rs. 708.5 cr and gross margin expanding 228 bps to 54.1%, though EBITDA margin dipped to 17.8%. The company closed the year with Rs. 704.2 cr in cash, invested Rs. 172.9 cr in capex (largely for scaling its Goa manufacturing unit), and commercialized 58 new SKUs with 79 more in the pipeline.
This is a positive result for shareholders, showcasing record-breaking growth, strong cash reserves, and a healthy product pipeline across geographies. Investors may view this favorably, though the slight Q4 EBITDA margin contraction and Rs. 13.6% sequential PAT decline are minor points to watch.